MMQCI
MMQCI is a privately held manufacturer of synthetic, non-infectious external quality controls for molecular diagnostic testing, serving clinical laboratories globally across infectious, inherited, and oncology disease applications on BioFire, Roche, GeneXpert, QIAGEN, Diasorin, and other major molecular platforms.
- Company typePrivate
- Founded2000
- HeadquartersSaco, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MMQCI does
Maine Molecular Quality Controls, Inc. (MMQCI) is a privately held, founder-owned specialty manufacturer of external quality control products for molecular diagnostic testing, headquartered and produced at an ISO 13485:2016 / MDSAP-certified cGMP facility in Saco, Maine. Founded in January 2000 by Joan Gordon (President/CEO) and Dr. Clark Rundell (VP Research) — both formerly of Maine Medical Center — the company builds its products on Rundell's patented process for stabilizing target nucleic acid constructs, yielding synthetic, non-infectious, multiplex DNA/RNA controls suspended in a defined matrix. The portfolio spans three brands (INTROL assayed controls, Birlinn platform-agnostic unassayed controls, and platform-specific SKUs) covering infectious disease (respiratory panels, GI, blood culture ID, meningitis/encephalitis, TB, tropical fever, Ebola), inherited disease (cystic fibrosis CFTR panels including NGS workflows, thrombophilia FII/FV Leiden/MTHFR, hereditary hemochromatosis), and oncology (BCR-ABL p210/p190 with WHO-traceable IS reporting, NPM1, PML-RARA, bladder cancer), with deep instrument compatibility across BioFire FilmArray, Roche cobas eplex, Cepheid GeneXpert, QIAGEN QIAstat-Dx, Diasorin LIAISON PLEX/Verigene, Hologic Panther Fusion, Abbott Alinity, and BD Max systems.
MMQCI operates a B2B enterprise sales motion targeting clinical laboratories and molecular diagnostic facilities globally, accepting orders via web form, email, phone, and fax with Net 30 terms and shipping to 60+ countries across 5 continents through direct sales and local distributors. Products are sold as one-time consumable purchases (typical 18-36 month shelf life) at quote-based pricing with annual February price-list updates, and are offered as either IVD (FDA-cleared / CE-IVD) or RUO depending on regulatory status and customer region. The company maintains a close co-development relationship with bioMérieux (parent of BioFire Diagnostics) and is funded exclusively through operating cash flow and early-stage grants from the National Institutes of Health and Maine Technology Institute, with no institutional equity capital. With a sub-10 employee headcount and a 25-year operating history, MMQCI exemplifies a durable, founder-led niche specialty life-sciences manufacturer.
MMQCI firmographics
Firmographics- Name
- MMQCI
- Legal name
- Maine Molecular Quality Controls, Inc.
- Website
- https://mmqci.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MMQCI is a privately held manufacturer of synthetic, non-infectious external quality controls for molecular diagnostic testing, serving clinical laboratories globally across infectious, inherited, and oncology disease applications on BioFire, Roche, GeneXpert, QIAGEN, Diasorin, and other major molecular platforms.
- Ownership category
- akta.pro rank
MMQCI industry classification
Industry- Product category
- Molecular Diagnostic Quality Controls (IVD medical device reagents)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
- akta.pro secondary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where MMQCI is headquartered
LocationHeadquarters
- HQ city
- Saco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MMQCI business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain
Revenue model
- Molecular Quality Control Products: One-time purchase of quality control products used in molecular diagnostic testing. Controls are consumables with typical shelf life of 18-36 months from date of manufacture. Products available as IVD (In Vitro Diagnostic) or RUO (Research Use Only) depending on regulatory status and customer region.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard product pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
MMQCI product offering
Product offeringCore offering
MMQCI manufactures and sells external quality control (QC) products for clinical molecular diagnostic testing. The product line consists of synthetic, non-infectious nucleic-acid control panels used by clinical laboratories to monitor the performance of molecular assays for inherited disease (cystic fibrosis, thrombophilia, hereditary hemochromatosis), infectious disease (respiratory, gastrointestinal, bloodstream, meningitis/encephalitis, tuberculosis, tropical fever, Ebola, SARS-CoV-2/influenza/RSV), and oncology (BCR-ABL, NPM1, PML-RARA, bladder cancer) on major platforms including BioFire FilmArray, Roche cobas eplex, Cepheid GeneXpert, QIAGEN QIAstat-Dx, Diasorin LIAISON PLEX/Verigene, Hologic Panther Fusion, Abbott Alinity, and BD Max.
Product overview
MMQCI (Maine Molecular Quality Controls) is a manufacturer of external quality control products for molecular diagnostic testing. The portfolio consists of multiple product lines organized by testing category and platform compatibility: (1) BioFire Controls for BIOFIRE FILMARRAY systems including RP2.1/RP2.1plus, GI, BCID2, Pneumonia, JI, ME, Ebola, TF, and SPOTFIRE/RSP panels; (2) ePlex Controls for Roche cobas eplex systems covering RP, RP2, RP3, BCID-FP, BCID-GP, and BCID-GN panels; (3) GeneXpert Controls for Cepheid systems including TB panels (M110, M114, M114plus, TB-XDR, TBNEG-30), SARS-CoV-2, Carba-R, FII/FV, and oncology panels (BCR-ABL, NPM1, PML-RARA, Bladder Cancer); (4) QIAstat-Dx Controls for QIAGEN systems; (5) LIAISON PLEX and Verigene Controls for Diasorin systems; (6) Birlinn unassayed Controls compatible with most platforms and LDTs for CoV2-Flu-RSV, HH Panel, and BCR-ABL p210; (7) CF Testing Controls (INTROL CF Panels I/II/III and NGS CF Panels); (8) Oncology Testing Controls (BCR-ABL IS Panels, NPM1, PML-RARA, Bladder Cancer); and (9) Thrombosis Genotype Panels. The products are manufactured under ISO 13485:2016 and MDSAP certifications.
Differentiator
Problem solved
Functional benefit
Brands
- Birlinn: Unassayed controls compatible with most platforms and LDTs. The name is anchored in Scottish Gaelic for swift, stalwart Viking ship. Birlinn controls feature large sequence coverage and lot-to-lot consistency tested over multiple sites, instruments, operators, and cartridge lots.
- INTROL
Products and services
- BioFire® RP2.1/RP2.1plus Control Panel M441 External quality control for the BioFire RP2.1/RP2.1plus Respiratory Panel on FilmArray systems, monitoring detection of respiratory pathogens. Used by clinical molecular diagnostics laboratories.
- FilmArray® GI Control Panel M238 External quality control for the BioFire FILMARRAY Gastrointestinal (GI) Panel, monitoring detection of 22 gastrointestinal pathogens. Used by clinical microbiology laboratories performing syndromic GI testing.
- FilmArray® BCID2 Control Panel M416 External quality control for the FilmArray BCID2 Blood Culture Identification Panel, monitoring detection of gram-positive and gram-negative bacteria, resistance genes, and yeast. Developed in close collaboration with bioMérieux/BioFire.
- FilmArray® Pneumonia/Pneumonia plus Control M340 External quality control for the FilmArray Pneumonia/Pneumonia plus Panel, monitoring detection of respiratory viral and bacterial targets for lower respiratory tract infection testing.
- BioFire® JI Control Panel M420 External quality control for the BioFire Joint Infection (JI) Panel on FilmArray systems, monitoring detection of gram-positive and gram-negative bacteria, resistance genes, and yeast in synovial fluid testing.
- BioFire® ME Control Panel M262 External quality control for the BioFire Meningitis/Encephalitis (ME) Panel on FilmArray systems, monitoring detection of pathogens in cerebrospinal fluid.
- FilmArray® Ebola Control Panel M251 Quality control for presumptive detection of Ebola Zaire virus on the FilmArray BioThreat-E test.
- FilmArray® TF Control Panel M527 External quality control for the BioFire FILMARRAY Tropical Fever Panel, monitoring detection of Chikungunya virus, Dengue virus, Plasmodium spp., Plasmodium falciparum, Plasmodium vivax/ovale, and Leptospira spp. on the BIOFIRE FILMARRAY 2.0 or Torch systems.
- SPOTFIRE® RSP Pos & Neg Controls M425 External quality control for the BIOFIRE SPOTFIRE Respiratory Panel (and variants) on the SPOTFIRE System.
- eplex RP Control M306 External quality control for the cobas eplex Respiratory Pathogen (RP) Panel on the Roche cobas eplex system.
- eplex RP2 Control M451 External quality control for the cobas eplex Respiratory Pathogen Panel 2 (RP2) on the Roche cobas eplex system.
- eplex RP3 Control M530 External quality control for the cobas eplex Respiratory Pathogen Panel 3 (RP3) on the Roche cobas eplex system.
- eplex BCID-FP Control M320v1.1 External quality control for the cobas eplex Blood Culture Identification Fungal Pathogen (BCID-FP) Panel on the Roche cobas eplex system.
- eplex BCID-GP Control M323v1.1 External quality control for the cobas eplex Blood Culture Identification Gram-Positive (BCID-GP) Panel on the Roche cobas eplex system.
- eplex BCID-GN Control M326 External quality control for the cobas eplex Blood Culture Identification Gram-Negative (BCID-GN) Panel on the Roche cobas eplex system.
- Xpert SARS-CoV-2 Control Panel M430 External quality control for the Xpert Xpress CoV-2 plus assay on Cepheid GeneXpert systems.
- Xpert Carba-R QC Panel M219 Quality control for the Xpert Carba-R Assay monitoring detection of carbapenem resistance genes on Cepheid GeneXpert systems.
- INTROL® TB Panel M110 Quality control for molecular detection of Mycobacterium tuberculosis and MDR-TB mutations, intended for clinical TB testing laboratories.
- INTROL® TB Panel M114 Quality control for GeneXpert-based MTB testing, including detection of drug-resistant TB variants.
- INTROL® TB Panel M114plus Quality control for GeneXpert MTB assays verifying detection of MTB and key drug-resistance markers.
- INTROL® TB-XDR Panel M345 Quality control for the Xpert MTB/XDR assay monitoring detection of extensively drug-resistant tuberculosis on Cepheid GeneXpert.
- INTROL® TBNEG-30 Negative control for GeneXpert MTB assays confirming absence of M. tuberculosis DNA.
- QIAstat-Dx RP SARS-CoV-2 Control Panel External quality control for the QIAstat-Dx Respiratory Panel on QIAGEN QIAstat-Dx systems, intended for respiratory pathogen QC.
- QIAstat-Dx GI 2 Control Panel External quality control for the QIAstat-Dx Gastrointestinal Panel 2 on QIAGEN QIAstat-Dx systems.
- LIAISON PLEX RP Control Panel M518 External quality control for the LIAISON PLEX Respiratory Flex Assay on the Diasorin LIAISON PLEX System.
- Verigene® RP Flex Control Panel M270 Quality control for the Verigene Respiratory Pathogen Flex Panel on Diasorin Verigene systems.
- INTROL® CF Panel I Control v.02 Quality control for cystic fibrosis testing, monitoring 38 CFTR mutations including ACMG/ACOG-recommended variants and polymorphisms. Used by clinical genetics laboratories.
- INTROL® CF Panel II Control Quality control for cystic fibrosis testing, monitoring 54 CFTR mutations including ACMG/ACOG-recommended variants.
- INTROL® CF Panel III Control Quality control for cystic fibrosis testing, monitoring 79 CFTR mutations including ACMG/ACOG-recommended variants.
- NGS CF Control Panel G211 v1.1 Quality control for Next Generation Sequencing workflows for the CFTR gene, monitoring insertions, deletions, and homopolymer variants.
- NGS CF Control Panel G211plus Expanded quality control for Next Generation Sequencing workflows for the CFTR gene with broader variant coverage.
- INTROL® Thrombosis Genotype Panel Quality control for Factor II, Factor V Leiden, and MTHFR gene mutations associated with thrombotic events, used in clinical genetics and thrombophilia testing.
- Xpert FII & FV Genotype Panel G109 Quality control for Factor II G20210A and Factor V Leiden G1691A detection on Cepheid GeneXpert systems.
- Birlinn® HH Panel G203 Unassayed control for hereditary hemochromatosis mutations (H63D, S65C, C282Y), compatible with most platforms and LDTs.
- Xpert BCR-ABL IS Panel C130 Assayed external quality control for quantitative detection of BCR-ABL1 p210 translocation transcripts on Cepheid GeneXpert systems, with values for International Scale reporting.
- Xpert BCR-ABL IS p210 Panel C206 Quality control for BCR-ABL1 p210 quantification using the Xpert BCR-ABL Ultra assay on Cepheid GeneXpert systems.
- Xpert BCR-ABL1 p190 Control Panel C183 Reference material for monitoring quantitative detection of the BCR-ABL1 p190 translocation on Cepheid GeneXpert systems.
- Xpert NPM1 Control Panel C194v1.1 Assayed external quality control for quantitative detection of NPM1 mutant transcripts on Cepheid GeneXpert systems.
- Xpert PML-RARA Control Panel C215 Reference material for quantitative detection of PML-RARA transcript isoforms on Cepheid GeneXpert systems.
- Xpert Bladder Cancer Panel C104 Quality control for qualitative detection of bladder cancer RNA transcripts (CRH, IGF2, UPK1B, ANXA10, ABL1) on Cepheid GeneXpert systems.
- Birlinn® CoV2-Flu-RSV Control Panel M509 Unassayed quality control compatible with most platforms and LDTs for monitoring detection of SARS-CoV-2, Influenza A/B, and Respiratory Syncytial Virus (RSV); compatible with 15+ assays across major molecular platforms.
- Birlinn® BCR-ABL1 p210 IS Panel C230 Unassayed control for BCR-ABL1 p210 with WHO-traceable values for International Scale conversion, compatible with multiple platforms.
- Birlinn® BCR-ABL1 p210 IS Control Panel C240 Unassayed control for BCR-ABL1 p210 monitoring with WHO-traceable values, compatible with multiple platforms.
Companies that use MMQCI
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
MMQCI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
Feature3 records
MMQCI partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- bioMérieuxcoreMMQCI works in close collaboration with bioMérieux to review and optimize formulation of FilmArray BCID2 Positive Control Panel M416. BioMérieux is the parent company of bioFire Diagnostics, manufacturer of the BioFire FilmArray systems for which MMQCI produces quality controls.
- International DistributorscoreMMQCI has local distributors available to support customers in 60+ countries across 5 continents. Controls are classified as medical devices and ship under HS code 3822.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
MMQCI competitors and assessment
Company assessmentDirect peers
- SeraCare (LGC Clinical Diagnostics): SeraCare, now part of LGC Group, is the most direct comparable: it manufactures reference materials and quality controls (including AccuPlex synthetic molecular controls) used by clinical laboratories to validate molecular diagnostic assays—the same core product category as MMQCI's controls.
- ZeptoMetrix: ZeptoMetrix manufactures external quality controls and reference materials for infectious disease molecular testing, overlapping directly with MMQCI's respiratory, GI, blood culture, and tropical fever product lines.
- Qnostics: Qnostics produces molecular quality controls and external run controls for infectious disease and infectious-molecular assays; it directly competes in the same clinical laboratory QC category MMQCI serves.
- Microbiologics: Microbiologics supplies biological reference materials, controls, and standards used in clinical and molecular microbiology, overlapping with MMQCI's infectious disease QC portfolio for pathogens, TB, and antimicrobial resistance targets.
Broad incumbents
- Bio-Rad Laboratories: Bio-Rad is a broad life-science tools and clinical diagnostics incumbent with a sizable molecular QC and quality controls business; while not a pure-play niche molecular QC vendor like MMQCI, it competes for the same clinical-lab QC budget across molecular and immunology assays.
- bioMérieux: bioMérieux is the parent of BioFire Diagnostics (FilmArray systems), for which MMQCI manufactures multiple control panels under a co-development relationship. As both an OEM partner and a vertically integrated diagnostics company, bioMérieux is the most strategically important adjacent peer.
- Cepheid (Danaher Diagnostics): Cepheid manufactures the GeneXpert systems for which MMQCI produces controls covering TB, SARS-CoV-2, Carba-R, FII/FV, BCR-ABL, NPM1, PML-RARA, and Bladder Cancer assays. It is a critical channel partner and a potential vertical integrator of QC products.
- ELITech Group: ELITech develops and distributes molecular diagnostic instruments and reagents and supplies laboratory quality controls to clinical labs across molecular diagnostics, making it a broader incumbent competing for similar QC wallet share.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MMQCI social profiles
Digital presenceMMQCI compliance and trust
Trust signalCompliance2 records
MMQCI financial estimates
Financial estimateRevenue estimate
Valuation estimate
MMQCI leadership team
Management profileNumber of profiles
Profiles4 records
MMQCI funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MMQCI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MMQCI
What does MMQCI do?
MMQCI manufactures and sells external quality control (QC) products for clinical molecular diagnostic testing. The product line consists of synthetic, non-infectious nucleic-acid control panels used by clinical laboratories to monitor the performance of molecular assays for inherited disease (cystic fibrosis, thrombophilia, hereditary hemochromatosis), infectious disease (respiratory, gastrointestinal, bloodstream, meningitis/encephalitis, tuberculosis, tropical fever, Ebola, SARS-CoV-2/influenza/RSV), and oncology (BCR-ABL, NPM1, PML-RARA, bladder cancer) on major platforms including BioFire FilmArray, Roche cobas eplex, Cepheid GeneXpert, QIAGEN QIAstat-Dx, Diasorin LIAISON PLEX/Verigene, Hologic Panther Fusion, Abbott Alinity, and BD Max.
Is MMQCI a public or private company?
MMQCI is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MMQCI founded?
MMQCI was founded in 2000. It employs 1 to 10 people.
Where is MMQCI based?
MMQCI is headquartered in Saco, United States, in the North America region.
How does MMQCI make money?
One revenue line is on record: molecular Quality Control Products.
Who are MMQCI's main competitors?
Direct peers on record are SeraCare (LGC Clinical Diagnostics), ZeptoMetrix, Qnostics and Microbiologics. Broad incumbents are Bio-Rad Laboratories, bioMérieux, Cepheid (Danaher Diagnostics) and ELITech Group.
Does MMQCI have an API?
No public API is recorded for MMQCI.
What industry is MMQCI in?
MMQCI's product category is Molecular Diagnostic Quality Controls (IVD medical device reagents). Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.